A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma.
In: Stem Cell Week, 2024, S. 16-16
serialPeriodical
Zugriff:
A clinical trial, NCT06172296, is being conducted to test the effectiveness of adding dinutuximab to standard treatment for children with high-risk neuroblastoma. The trial will evaluate the combination of dinutuximab with chemotherapy, surgery, radiation, and stem cell transplantation. It aims to assess survival rates, response rates, adverse events, and other outcome measures. The trial is set to start in 2024 and is expected to be completed by 2029. This phase III trial aims to determine the effectiveness of adding dinutuximab to induction chemotherapy for the treatment of children with high-risk neuroblastoma. The trial will assess survival rates, response rates, toxicities, and explore biomarkers and markers of minimal residual disease. Various treatments and procedures, including radiation, dinutuximab, and scans, are involved in the study. The study is in Phase 3 and is designed as a randomized intervention. The primary purpose is treatment, and patients are followed up after completing the study treatment. The document provides a list of medications, procedures, and alternative names related to cancer treatment. It also provides a list of drugs, procedures, and alternative names for a clinical trial. The trial, known as ANBL2131, is being conducted by the National Cancer Institute (NCI) and aims to study the treatment of high-risk neuroblastoma in patients up to 30 years old. The trial is investigating various aspects of the disease, including genetics [Extracted from the article]
Copyright of Stem Cell Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma.
|
---|---|
Zeitschrift: | Stem Cell Week, 2024, S. 16-16 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1537-1360 (print) |
Sonstiges: |
|